Moonwalk Biosciences announces $70M Series B to advance adipose-targeted RNai therapies
Moonwalk Biosciences announced a $70 million Series B financing to advance adipose-targeted RNai therapies for obesity and cardiometabolic diseases.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.